MEDVi vs Henry Meds

Both sell tirzepatide. MEDVi costs $399 a month and Henry Meds costs $449, a difference of $50 a month or about $600 a year. The desk reads it as follows.

MEDVi is tablet and injection choice. Henry Meds is sublingual and oral formats. They are not aimed at the same person, and the cheaper one is not automatically the right answer — though on this board it usually is.

Advert against bill. MEDVi advertises $399 and bills $399; Henry Meds advertises $399 and bills $449. The gaps are different sizes, which means comparing the two on their advertised prices gives you the wrong answer.

Side by side

Prices verified 2026-09-18. "True monthly cost" is what you are billed in month two, once any introductory rate has lapsed and any membership has renewed.

The split

On every attribute we track these two behave identically — same answer on dose pricing, commitment, pharmacy disclosure, formats, insurance and what the price includes. When that happens the decision really is just the monthly figure, and MEDVi is $50 a month cheaper.

What each puts on the record: MEDVi

• Compounded tirzepatide injections listed at $399/month.
• Tirzepatide tablet pricing is quoted after the intake questionnaire rather than published up front.

Where it wins: Injection pricing is consistent between the first month and renewals. Watch for: You have to complete intake before seeing tablet pricing. Injection pricing is published at $399.

What each puts on the record: Henry Meds

• Injectable tirzepatide listed at $399 for the first month and $449/month recurring.
• Oral tirzepatide tablets listed at $299 first month, $349/month recurring.
• Compounded semaglutide injection around $297/month; sublingual around $249/month with a $179/month tier.
• Three-month oral tirzepatide supply $1,047, or $891 paid in full.
• Three-month oral semaglutide supply $747, or $537 paid in full.
• Advertising states pricing "starts at $179/month", which corresponds to the lowest sublingual tier.

Where it wins: No membership fee layered on top of medication. Watch for: The advertised "starts at $179" is the sublingual tier. Weekly injectable tirzepatide renews at $449/month.

In each one’s favour

MEDVi.

• Injection pricing is consistent between the first month and renewals.
• Tablet option for people who will not inject.

Henry Meds.

• No membership fee layered on top of medication.
• Real choice of sublingual, oral tablet and injection.

How they score

Henry Meds scores higher overall at 3 out of 5. The weights are published on how we rate, and so is the note about which of these is our paid featured partner.

The desk’s call

• Pick MEDVi if cost is the binding constraint. Over a year the gap is about $600, which is real money for the same class of medication.
• Pick Henry Meds if what it does better matters to you — no membership fee layered on top of medication.
• Ask both which pharmacy compounds the medication and whether it is a 503A or 503B facility. Neither publishes it.

The verdict

On the board, MEDVi at $399 a month is the more defensible choice on arithmetic alone. Henry Meds earns its premium only if you will actually use what it does differently. Read the full reviews before deciding: MEDVi and Henry Meds.

How they sit against everyone else